Rice Hall James & Associates’s Genpact G Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.9M Buy
833,996
+129,872
+18% +$4.27M 1.12% 27
2026
Q1
$26.2M Buy
704,124
+445,743
+173% +$18.4M 1.46% 20
2025
Q4
$12.1M Buy
+258,381
New +$11.2M 0.67% 49
2022
Q2
Sell
-36,468
Closed -$1.59M 285
2022
Q1
$1.59M Sell
36,468
-517
-1% -$24K 0.06% 224
2021
Q4
$1.96M Hold
36,985
0.07% 214
2021
Q3
$1.76M Sell
36,985
-1,206
-3% -$59.9K 0.06% 225
2021
Q2
$1.74M Buy
38,191
+1,026
+3% +$46.4K 0.06% 229
2021
Q1
$1.59M Sell
37,165
-2,248
-6% -$93.3K 0.05% 234
2020
Q4
$1.63M Sell
39,413
-7,236
-16% -$286K 0.06% 218
2020
Q3
$1.82M Sell
46,649
-2,756
-6% -$109K 0.07% 178
2020
Q2
$1.8M Sell
49,405
-1,156
-2% -$39.1K 0.08% 158
2020
Q1
$1.48M Sell
50,561
-391
-0.8% -$15.3K 0.08% 165
2019
Q4
$2.15M Buy
+50,952
New +$2.04M 0.07% 160

Other funds holding G

Rice Hall James & Associates's G Position: Q2 2026 in Review

Rice Hall James & Associates increased its Genpact (G) stake by 18% in Q2 2026, buying an estimated $4.27M and bringing the position to 833,996 shares worth $22.9M. The position accounts for 1.12% of the portfolio, ranked #27.

Rice Hall James & Associates first reported a position in G in Q4 2019 and has held it in 13 quarters since. The position peaked at $26.2M in Q1 2026. 479 funds tracked by Wall St. Rank hold G as of Q2 2026.

  • Rice Hall James & Associates held 833,996 shares of Genpact worth $22.9M as of Q2 2026.
  • Rice Hall James & Associates bought 129,872 Genpact shares in Q2 2026, an estimated $4.27M.
  • Genpact made up 1.12% of Rice Hall James & Associates's portfolio in Q2 2026, its #27 holding.
  • Rice Hall James & Associates first reported a position in Genpact in Q4 2019 and has held it in 13 quarters since.
  • Rice Hall James & Associates's Genpact position peaked at $26.2M in Q1 2026.
  • 479 funds tracked by Wall St. Rank held Genpact as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.